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Background. Pregnantwomenareahigh-riskgroupforinﬂuenza-associatedcomplicationsandhospitalizations.
Methods. To examine the immunogenicity of a monovalent 2009 inﬂuenza A (H1N1) vaccine among pregnant
women, a prospective cohort study was performed at 2 medical institutes of obstetrics in Japan. One hundred ﬁfty
subjects received 2 subcutaneous doses of vaccine 3 weeks apart. The hemagglutination inhibition antibody titer was
measured in serum samples collected at 3 time points: before vaccination, 3 weeks after the ﬁrst dose, and 4 weeks
after the second dose.
Results. The ﬁrst dose of vaccine induced a >10-fold rise in the average level of antibody. The seroresponse rate
(>4-fold rise) was 91%, and the seroprotection rate (postvaccination titer >1:40) was 89%. The second dose of
vaccine conferred little additional induction of antibodies. Similar immune responses were observed irrespective of
body mass index before pregnancy, trimester, or age at vaccination. However, lesser immune response was shown in
subjects who had received the 2009–2010 seasonal inﬂuenza vaccine before the H1N1 vaccination.
Conclusions. A single dose of vaccine induced an adequately protective level of immunity in pregnant women.
The potential interference with seasonal vaccination requires a more thorough investigation to prepare for future
inﬂuenza pandemics.
Pregnant women are a high-risk group for inﬂuenza-as-
sociated complications and hospitalizations. Among
healthy pregnant women, excess deaths were documented
during the inﬂuenza pandemics of 1918–1919 and 1957–
1958 [1–3]. Higher hospitalization rates among pregnant
women were also reported in the 2009 inﬂuenza A
(H1N1) pandemic [4, 5]. Even in nonpandemic inﬂuenza
seasons, hospitalization rates were increased in all tri-
mesters of pregnancy [6, 7] and were particularly higher
in the third trimester or among women with underlying
illnesses [7–10]. Therefore, the control of inﬂuenza
among pregnant women is one of the most important
challenges in public health.
Inﬂuenza vaccination is the most effective method for
preventing inﬂuenza illness and its complications. The
World Health Organization guidelines that were pre-
paredfor the 2009 inﬂuenza A(H1N1)pandemicplaced
pregnant women in the highest priority group to receive
vaccination.Therefore, the Japanese governmentrevised
the package insert for inﬂuenza vaccine, which had
originally indicated that pregnancy was a contraindica-
tion for vaccination, and advised pregnant women to
receive the vaccination.
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reactogenicity of the inﬂuenza vaccine administered to pregnant
women. This lack of scientiﬁc evidence might contribute to the
low level of vaccine coverage among pregnant women. The
annual inﬂuenza vaccination has been recommended to preg-
nant women in the United States for more than a decade, but
vaccine coverage has remained at a low level, compared with
that of other high-risk groups [11]. Pregnant women may be
reluctant to receive the vaccination because they are concerned
about the effect of any medications (including vaccines) on their
fetuses. However, 1 report has found that the attitude of health
care providers also contributes to the lack of vaccine coverage
among pregnant women. According to this report, 30% of
health care providers did not believe in the safety and effec-
tiveness of inﬂuenza vaccine among pregnant women, and 60%
of health care providers did not know that pregnant women
were at high risk for inﬂuenza-associated complications [12]. To
achieve a high rate of inﬂuenza vaccination among pregnant
women, it is essential to accumulate evidence about the in-
ﬂuenza disease burden and the immunogenicity, reactogenicity,
and effectiveness of vaccination among this group.
Studies of the 2009 pandemic inﬂuenza vaccine found that
a single dose of vaccine with 15 lg of antigen induced sufﬁcient
immune responses among adults [13–16]. However, most of
these studies excluded pregnant women from the immunoge-
nicity analyses. To provide some information in a national
decision about the number of doses of a monovalent 2009 in-
ﬂuenza A (H1N1) vaccine to recommend for pregnant women,
the present study examined the immunogenicity of 2 doses of
vaccine among pregnant women in Japan. When researchers are
evaluating the antibody induction by a vaccine, the effect of
potential predictors,such as age and prevaccination titer, should
be considered [17]. Thus, the induction of serum hemaggluti-
nation inhibition (HAI) antibody was assessed by 3 conven-
tional parameters—the fold rise, the seroresponse rate (>4-fold
rise), and the seroprotection rate (postvaccination titer
>1:40)—and the independent effects of potential predictors for
antibody induction were then evaluated.
METHODS
Study Subjects
The study subjects were pregnant women recruited from 2
medical institutions of obstetrics in Osaka, Japan. All subjects
provided written informed consent after the nature and pos-
sible consequences of the study had been explained. The study
protocol was approved by the ethics committee at the Osaka
City University Graduate School of Medicine and was per-
formed in accordance with the Declaration of Helsinki. None of
the applicants met the exclusion criteria for eligibility, in-
cluding a history of 2009 inﬂuenza A (H1N1) infection, an
acute febrile illness or signs of severe acute illness at the time of
vaccination, a history of anaphylaxis due to vaccine compo-
nents, or other inappropriate condition to receive vaccination.
A total of 150 pregnant women were enrolled. The subjects
received 2 subcutaneous injections of the 2009 monovalent
inactivated inﬂuenza A (H1N1) vaccine into their arms 3 weeks
apart (Lot. NM001A; Kitasato). Each vaccine contained 15 lg
of hemagglutinin antigen. The vaccines did not contain thi-
merosal. The seed virus was prepared from reassortant vaccine
virus A/California/7/2009 NYMC X-179A (New York Medical
College), distributed by the Centers for Disease Control and
Prevention in the United States. The vaccine was prepared in
embryonated chicken eggs by using standard methods for the
production of seasonal trivalent inactivated vaccine.
Information Collection
At the time of recruitment, subjects completed a self-administered
questionnaire to collect the following information: age at vacci-
nation, height and body weight before pregnancy, underlying
illnesses (ie, heart disease, renal disease, liver disease, atopy, or
asthma), 2009–2010 seasonal inﬂuenza vaccination before
recruitment, and the date of vaccination (if vaccinated). The
2009–2010 seasonal inﬂuenza vaccine strains were A/Brisbane/
59/2007 (H1N1), A/Uruguay/716/2007 (H3N2), and B/Brisbane/
60/2008. Additionally, the subjects’ obstetricians completed
a structured questionnaire to collect the following clinical
information: gestational age, multiple pregnancy, and pregnancy-
induced complications (ie, anemia, pregnancy-induced hyper-
tension, or gestational diabetes).
Measurement of Antibody Titer
Serum samples were collected at 3 time points: before vaccina-
tion (S0); 3 weeks after the ﬁrst dose (S1); and 4 weeks after the
second dose (S2). All serum specimens were kept at –80Cu n t i l
assayed at the same time. Serum antibody levels to hemagglu-
tinin were measured by the standard microtiter HAI method
[18] with the same antigens as in the vaccine. All samples were
assayed at the Kitasato Institute in February 2010.
Statistical Analyses
The following outcomes were calculated to assess the immu-
nogenicity of inﬂuenza vaccine: the geometric mean titer; the
fold rise; the seroresponse rate (>4-fold rise); and the sero-
protection rate (postvaccination titer >1:40). For data pro-
cessing, titers ,1:10 were regarded as 1:5, and reciprocal
antibody titers were analyzed after logarithmic transformation.
The resultswere presentedin the original scale by calculating the
antilogarithm. Stratiﬁed analyses were performed to examine
the effect of the following potential confounders: body mass
index before pregnancy (tertile or ,25.1 and >25.1); trimester
(,16, 16–27, and >28 weeks); age at vaccination (tertile);
2009–2010 seasonal inﬂuenza vaccination (unvaccinated and
vaccinated); duration between seasonal vaccination and H1N1
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prevaccination titer (,1:10, 1:10–1:20, and >1:40). The signif-
icanceoffoldrisewithin acategorywasassessedbytheWilcoxon
signed-rank test, and intercategory comparisons were made by
either the Wilcoxon rank-sum test or the Kruskal-Wallis test.
The t test, v
2 test, or Mantel-extension method for the trend test
were alsousedwhereappropriate.Furthermore, theindependent
effects of potential confounders on antibody induction were
evaluated by logistic regression. The models were constructed
with seroresponse or seroprotection as the dependent variable
and the above-mentioned potential confounders as explanatory
variables. Odds ratios (ORs) and 95% conﬁdence intervals (95%
CIs) were calculated. All tests were 2-sided. All analyses were
performed using SAS, version 9.1.3 (SAS Institute).
RESULTS
A total of 150 pregnant women received the ﬁrst dose of vaccine
between 7 November and 27 November 2009, and serum sam-
ples at 3 weeks after the ﬁrst dose were collected from all of the
subjects. Among these women, 142 received the second dose
between3 Decemberand18December2009,andserum samples
at 4 weeks after the second dose were collected from 137 sub-
jects. All subjects had a singleton pregnancy. Only 1 subject
experienced a conﬁrmed inﬂuenza A virus infection (as de-
terminedbytherapid test) between the ﬁrst and the seconddose
and thus was excluded from the analyses. Eventually, data from
149 pregnant women were used for the immunogenicity anal-
yses of the ﬁrst dose, and data from 137 pregnant women were
used for the analyses of the second dose. None of the subjects
received both the 2009–2010 seasonal inﬂuenza vaccine and the
2009 monovalent inﬂuenza A (H1N1) vaccine at the same time.
Nosevereadverseeventsforthepregnantwomenortheirfetuses
occurred after the ﬁrst or second dose.
The subject characteristics are shown in Table 1. The mean
age was 30.6 years, and half of the women were in the third
trimester. Only a small number of subjects had pregnancy-
induced complications, such as anemia (3%) or hypertension
(1%). A total of 23% of the subjects received the 2009–2010
seasonal inﬂuenza vaccine before the H1N1 vaccination
(Table 1).
The results of the antibody response are summarized in
Table 2. The ﬁrst dose of vaccine induced an average increase in
the HAI antibody level of >10-fold (P , .001). The serores-
ponse rate was 91% (95% CI, 86%–96%), and the seropro-
tection rate was 89% (95% CI, 84%–94%). According to
conventionally used international criteria [19, 20], the sero-
conversion rate was at the same level as the seroresponse rate
(91%; 95% CI, 86%–96%). The second vaccination conferred
little additional induction of antibodies.
The parameters of immunity (ie, fold rise, seroresponse
rate, and seroprotection rate) were similar irrespective of body
mass index before pregnancy, trimester, or age at vaccination
(Table 2). However, women who had received the 2009–2010
seasonal inﬂuenza vaccine before the H1N1 vaccination had
a smaller immune response. The women who received the
seasonal vaccination and H1N1 vaccination within 19 days ex-
hibited a lower fold rise, seroresponse rate, and seroprotection
rate (after the ﬁrst dose: P 5 .021; P 5 .001; and P , .001 for
each). On the other hand, when comparing the results across
3-tiered prevaccination titers, the mean fold rises were signiﬁ-
cantlyloweramongthosewithhigherprevaccinationtiters(after
the ﬁrst dose, P , .001). Subjects with higher prevaccination
titers also had lower seroresponse rates but higher seropro-
tection rates with clear dose-response relationships (after the
ﬁrst dose, P , .001 and P 5 .052).
Even after considering the effect of potential confounders, the
group who had received the 2009–2010 seasonal inﬂuenza vac-
cine, especially within a short period (<19 days) between sea-
sonal vaccination and H1N1 vaccination, had a decreased
seroresponse after the ﬁrst dose of H1N1 vaccine (Table 3). The
adjusted OR (95% CI) of the vaccinated group was 0.15 (0.03–
Table 1. Characteristics in Pregnant Women
Characteristics
Study subjects
(N 5 149)
Body mass index before pregnancy
Mean (SD) 20.7 (2.5)
Median (range) 20.1 (16.9–30.8)
Age at H1N1 vaccination, years
Mean (SD) 30.6 (5.4)
Median (range) 31.0 (17–41)
Underlying illnesses before pregnancy
Heart disease 1 (1)
Liver disease 1 (1)
Atopic dermatitis 8 (5)
Drug allergy 7 (5)
Food allergy 24 (16)
Gestational age, weeks
First trimester (,16) 26 (17)
Second trimester (16–27) 46 (31)
Third trimester (281) 77 (52)
Pregnancy-induced complications
Pregnancy-induced hypertension
Present 1 (1)
Unknown 3
Anemia
Present 4 (3)
Unknown 3
Gestational diabetes
Present 0 (0)
Unknown 4
2009–2010 seasonal inﬂuenza
vaccination received
35 (23)
NOTE. Dataare expressed asno. (%) ofwomen,unlessotherwise indicated.
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Category N
Geometric mean
a Fold rise
a After ﬁrst vaccination
b After second vaccination
bc
Before vaccination
(S0)
After ﬁrst
vaccination (S1)
After second
vaccination (S2)
c S1/S0 S2/S0
c
>4-fold rise
No. (%)
>1:40
No. (%)
>4-fold rise
No. (%)
>1:40
No. (%)
Entire sample 149 8 139 114 17.1 14.1 136 (91) 132 (89) 123 (87) 124 (91)
Body mass index before pregnancy
,19.2 50 9 147 116 16.2 (P , .001) 12.9 (P , .001) 46 (92) 45 (90) 39 (87) 41 (91)
19.2–21.4 49 7 111 92 16.7 (P , .001) 14.1 (P , .001) 45 (92) 40 (82) 40 (91) 37 (84)
>21.5 50 9 164 137 18.4 (P , .001) 15.3 (P , .001) 45 (90) 47 (94) 44 (92) 46 (96)
(P 5 .06) (P 5 .30) (P 5 .35) (P 5 .88) (P 5 .91) (P 5 .72) (P 5 .53) (P 5 .41) (P 5 .40)
,25.1 140 8 133 113 16.3 (P , .001) 14.0 (P , .001) 127 (91) 123 (88) 114 (89) 115 (90)
>25.1 9 9 296 137 31.6 (P 5 .004) 16.0 (P , .001) 9 (100) 9 (100) 9 (100) 9 (100)
(P 5 .97) (P 5 .04) (P 5 .55) (P 5 .13) (P 5 .82) (P 5 1.00) (P 5 .60) (P 5 .60) (P 5 .60)
Trimester
First 26 11 144 112 12.6 (P , .001) 9.4 (P , .001) 24 (92) 22 (85) 19 (76) 23 (92)
Second 46 7 118 83 17.5 (P , .001) 12.6 (P , .001) 41 (89) 40 (87) 40 (91) 37 (84)
Third 77 8 152 142 18.6 (P , .001) 17.5 (P , .001) 71 (92) 70 (91) 64 (94) 64 (94)
(P 5 .05) (P 5 .63) (P 5 .06) (P 5 .49) (P 5 .13) (P 5 .86) (P 5 .34) (P 5 .02) (P 5 .43)
Age at H1N1 vaccination (years)
,29 46 8 136 126 17.5 (P , .001) 16.8 (P , .001) 42 (91) 41 (89) 37 (90) 37 (90)
29–33 50 8 125 93 16.0 (P , .001) 11.6 (P , .001) 45 (90) 43 (86) 42 (89) 42 (89)
>34 53 9 158 128 17.8 (P , .001) 14.7 (P , .001) 49 (92) 48 (91) 44 (90) 45 (92)
(P 5 .87) (P 5 .71) (P 5 .28) (P 5 .93) (P 5 .39) (P 5 .83) (P 5 .80) (P 5 .95) (P 5 .79)
2009–2010 seasonal inﬂuenza vaccination
Unvaccinated 114 8 159 127 20.3 (P , .001) 16.1 (P , .001) 108 (95) 105 (92) 102 (94) 101 (93)
Vaccinated 35 9 90 74 9.8 (P , .001) 8.4 (P , .001) 28 (80) 27 (77) 21 (75) 23 (82)
(P 5 .41) (P 5 .03) (P 5 .07) (P 5 .008) (P 5 .028) (P 5 .007) (P 5 .02) (P 5 .004) (P 5 .09)
Duration between seasonal vaccination and H1N1 vaccination
Unvaccinated 114 8 159 127 20.3 (P , .001) 16.1 (P , .001) 108 (95) 105 (92) 102 (94) 101 (93)
>20 days 17 8 120 101 15.4 (P , .001) 13.3 (P , .001) 17 (100) 15 (88) 14 (93) 13 (87)
<19 days 17 10 68 52 6.8 (P , .001) 5.0 (P 5 .002) 11 (65) 11 (65) 7 (54) 10 (77)
(P 5 .69) (P 5 .08) (P 5 .10) (P 5 .021) (P 5 .019) (P 5 .001) (P 5 .002) (P , .001) (P 5 .06)
Prevaccination titer
,1:10 92 5 121 93 24.2 (P , .001) 18.7 (P , .001) 89 (97) 78 (85) 79 (93) 72 (85)
1:10–1:20 46 13 173 152 13.0 (P , .001) 11.7 (P , .001) 43 (93) 43 (93) 40 (95) 42 (100)
>1:40 11 62 181 184 2.9 (P 5 .008) 2.8 (P 5 .016) 4 (36) 11 (100) 4 (40) 10 (100)
(P 5 .37) (P 5 .07) (P , .001) (P , .001) (P , .001) (P 5 .05) (P 5 .001) (P 5 .007)
NOTE.
a Wilcoxon signed-rank test for intracategory comparisons, and either the Wilcoxon rank-sum test or the Kruskal-Wallis test for intercategory comparisons.
b Seroresponse rate (>4-fold rise) and seroprotection rate (postvaccination titer >1:40). v
2 test between 2 categories and the Mantel-extension method for trend test among 3 categories.
c The results of 137 study subjects who received second dose of vaccination and provided serum sample after second vaccination.
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.0.80). A higher prevaccination titer was also independently
associated with a lower seroresponse (Trend P , .001).
As shown in Table 4, subjects with 2009–2010 seasonal in-
ﬂuenza vaccination also had a statistically signiﬁcant decrease in
OR for seroprotection to the 2009 pandemic inﬂuenza A
(H1N1) vaccine (OR, 0.24; 95% CI, 0.08–0.76). In contrast,
subjects with higher prevaccination titers had increased ORs
for seroprotection. There was no association between antibody
responses and body mass index before pregnancy, trimester, and
age at vaccination.
Additional analyses were conducted when the cut-off point of
duration between seasonal inﬂuenza vaccination and 2009
pandemic inﬂuenza A (H1N1)vaccination was changed from 20
days to 14 days. Among 10 subjects with seasonal vaccination
within 14 days, geometric mean titer levels at S0 and S1 were 10
and 49, respectively, which result in 4.9-fold rises after the ﬁrst
dose of H1N1 vaccination. The seroresponse rate was 60% and
the seroprotection rate was 50%. Multivariate analyses showed
that ORs of subjects with seasonal vaccination within 14 days
were lowered both for seroresponse and for seroprotection as
outcome index (for seroresponse, OR, 0.03; 95% CI, 0.004–0.26;
and for seroprotection, OR, 0.07; 95% CI, 0.01–0.35).
During the study periods, 6 subjects reported inﬂuenza-like
illness (deﬁned by acute febrile illness [temperature >38.0C]
with 1 or more respiratory symptoms [nasal discharge or runny
nose,sorethroat,orcough]).However,evenwhenthesesubjects
were excluded from the analyses, the results were almost un-
changed (data not shown).
DISCUSSION
The present study shows that a single dose of 2009 inﬂuenza A
(H1N1) vaccine induced sufﬁcient immune responses among
pregnant women irrespective of body mass index before
Table 3. Association Between Selected Characteristics and Seroresponse Rate (‡4-Fold Rise) After First Dose of Vaccination
Category n/N (%)
Crude analysis Multivariate model 1
a Multivariate model 2
b
OR (95% CI) P OR (95% CI) P OR (95% CI) P
Body mass index before pregnancy
,19.2 46/50 (92) 1.00 1.00 1.00
19.2–21.4 45/49 (92) 0.98 (.23–4.15) 0.98 0.34 (.05–2.47) 0.28 0.53 (.06–4.55) 0.56
>21.5 45/50 (90) 0.78 (.20–3.10) 0.73 0.42 (.06–3.14) 0.40 0.40 (.04–4.15) 0.44
(Trend P 5 .72) (Trend P 5 .38) (Trend P 5 .41)
Trimester
First 24/26 (92) 1.00 1.00 1.00
Second 41/46 (89) 0.68 (.12–3.80) 0.66 0.28 (.02–3.28) 0.31 0.30 (.02–5.30) 0.41
Third 71/77 (92) 0.99 (.19–5.22) 0.99 0.61 (.06–6.33) 0.68 0.39 (.03–5.72) 0.49
(Trend P 5 .86) (Trend P 5 .88) (Trend P 5 .60)
Age at H1N1 vaccination, years
,29 42/46 (91) 1.00 1.00 1.00
29–33 45/50 (90) 0.86 (.22–3.41) 0.83 0.95 (.17–5.44) 0.96 1.33 (.17–10.7) 0.79
>34 49/53 (92) 1.17 (.28–4.95) 0.84 4.09 (.48–34.6) 0.20 5.82 (.45–75.5) 0.18
(Trend P 5 .83) (Trend P 5 .20) (Trend P 5 .16)
2009–2010 seasonal inﬂuenza vaccination
Unvaccinated 108/114 (95) 1.00 1.00
Vaccinated 28/35 (80) 0.22 (.07–.71) 0.01 0.15 (.03–.80) 0.03
Duration between seasonal vaccination and H1N1 vaccination
Unvaccinated 108/114 (95) 1.00 1.00
>20 days 17/17 (100) Not applicable Not applicable
<19 days 11/17 (65) 0.10 (.03–.37) 0.001 0.03 (.004–.29) 0.002
(Trend P 5 .002) (Trend P 5 .003)
Prevaccination titer
,1:10 89/92 (97) 1.00 1.00 1.00
1:10–1:20 43/46 (93) 0.48 (.09–2.49) 0.39 0.27 (.04–1.86) 0.19 0.33 (.04–2.53) 0.29
>1:40 4/11 (36) 0.02 (.004–.10) ,.001 0.01 (.00–.07) ,.001 0.01 (.00–.09) ,.001
(Trend P , .001) (Trend P , .001) (Trend P 5 .001)
NOTE. Logistic regression model. CI, conﬁdence interval; OR, odds ratio.
a Model included body mass index before pregnancy, trimester, age at H1N1 vaccination, 2009–2010 seasonal inﬂuenza vaccination, and prevaccination titer.
b Model included body mass index before pregnancy, trimester, age at H1N1 vaccination, duration between seasonal and H1N1 vaccination, and
prevaccination titer.
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prior 2009–2010 seasonal inﬂuenza vaccination and a prevacci-
nation titer to A/California (H1N1-pdm) might affect the im-
mune responses to 2009 pandemic inﬂuenza A (H1N1)
vaccination. The immunity after the ﬁrst dose satisﬁed the in-
ternational licensing criteria of the European Agency for the
Evaluation of Medical Products and the US Food and Drug
Administration. The second dose of vaccine conferred little
additional induction of antibody. Previous studies showed that
single dose of 2009 inﬂuenza A (H1N1) vaccine (with 15 lgo f
antigen) achieved a protective level of antibody among 90%–
97% of healthy adults, which is similar to the seroprotection
level of 89% that was found in our study [13–16]. The results of
the present study agree with a previous review that indicated
that the antibody response to inﬂuenza vaccine was similar in
pregnant and nonpregnant women [21].
Aninverseassociation oftheprevaccinationtiter with the fold
rise and the seroresponse rate in serum HAI antibody, which is
known as the ‘‘law of initial values’’ or ‘‘negative feedback,’’ is
clearly demonstrated in the present study [22]. These effects
were independent of body mass index before pregnancy, tri-
mester, age at vaccination, or the status of 2009–2010 seasonal
inﬂuenza vaccination.
The 2009–2010 season, in which the present study was con-
ducted, was an exceptional inﬂuenza season in that 2 types of
inﬂuenza vaccine (2009 pandemic inﬂuenza A [H1N1] vaccine
and 2009–2010 seasonal inﬂuenza vaccine) were prevailing
because of the inﬂuenza A (H1N1) pandemic. In such a season,
optimal timing of each vaccination might be a very important
issue. Although the present study is limited because of a small
sample size, the results might be useful in addressing this point.
In the present study, the immune response to pandemic H1N1
vaccine was affected by recently received seasonal inﬂuenza
vaccination, suggesting a potential interference in immune
responses between the seasonal vaccination and pandemic in-
ﬂuenza A/H1N1 vaccination. However, a previous study found
Table 4. Association Between Selected Characteristics and Seroprotection Rate (Titer ‡ 1:40) After First Dose of Vaccination
Category n/N (%)
Crude analysis Multivariate model 1
a Multivariate model 2
b
OR (95% CI) P OR (95% CI) P OR (95% CI) P
Body mass index before pregnancy
,19.2 41/46 (89) 1.00 1.00 1.00
19.2–21.4 39/48 (81) 0.53 (.16–1.72) 0.29 0.80 (.21–3.07) 0.74 0.78 (.20–3.09) 0.72
>21.5 41/44 (93) 1.67 (.37–7.44) 0.50 2.36 (.46–12.3) 0.31 1.65 (.31–8.86) 0.56
(Trend P 5 .58) (Trend P 5 .29) (Trend P 5 .58)
Trimester
First 18/22 (82) 1.00 1.00 1.00
Second 37/43 (86) 1.37 (.34–5.47) 0.66 2.07 (.46–9.33) 0.34 2.21 (.48–10.2) 0.31
Third 66/73 (90) 2.10 (.55–7.96) 0.28 3.18 (.71–14.3) 0.13 3.35 (.72–15.6) 0.12
(Trend P 5 .26) (Trend P 5 .14) (Trend P 5 .14)
Age at H1N1 vaccination, years
,29 38/43 (88) 1.00 1.00 1.00
29–33 40/47 (85) 0.75 (.22–2.57) 0.65 0.80 (.20–3.18) 0.76 0.84 (.20–3.45) 0.81
>34 43/48 (90) 1.13 (.30–4.21) 0.85 1.04 (.24–4.55) 0.95 1.27 (.27–5.91) 0.76
(Trend P 5 .84) (Trend P 5 .94) (Trend P 5 .74)
2009–2010 seasonal inﬂuenza vaccination
Unvaccinated 98/107 (92) 1.00 1.00
Vaccinated 23/31 (74) 0.26 (.09–.76) 0.01 0.24 (.08–.76) 0.02
Duration between seasonal vaccination and H1N1 vaccination
Unvaccinated 98/107 (92) 1.00 1.00
>20 days 14/16 (88) 0.64 (.13–3.29) 0.60 0.59 (.11–3.29) 0.55
<19 days 9/15 (60) 0.14 (.04–.48) 0.002 0.12 (.03–.48) 0.003
(Trend P 5 .003) (Trend P 5 .004)
Prevaccination titer
,1:10 78/92 (85) 1.00 1.00 1.00
1:10–1:20 43/46 (93) 2.57 (.70–9.45) 0.16 2.82 (.69–11.5) 0.15 2.97 (.71–12.4) 0.14
NOTE. Logistic regression model. 138 study subjects were included for the analyses, because 11 subjects with prevaccination titer of >1:40 were excluded. CI,
conﬁdence interval; OR, odds ratio.
a Model included body mass index before pregnancy, trimester, age at H1N1 vaccination, 2009–2010 seasonal inﬂuenza vaccination, and prevaccination titer.
b Model included body mass index before pregnancy, trimester, age at H1N1 vaccination, duration between seasonal and H1N1 vaccination, and
prevaccination titer.
1306 d JID 2011:203 (1 May) d Ohfuji et al.that the simultaneous administration of seasonal and pandemic
H1N1 vaccine could induce sufﬁcient levels of antibody to both
the seasonal and the pandemic H1N1 vaccine strains [23]. An-
other study showed that when the seasonal and pandemic H1N1
vaccines were separately administered, the geometric mean titer
level to the pandemic H1N1 vaccine strain was lower among the
seasonal-vaccinated group than among the unvaccinated group,
although the difference was not statistically signiﬁcant [16].
Because there is still only limited evidence, further studies are
necessary to examine the potential interference across inﬂuenza
vaccines.
No severe adverse events occurred among pregnant women
and their fetuses throughout the study period. One fetal death
was reported on the day after vaccination; however, a pathologic
diagnosis indicated that the fetal death had occurred >7d a y s
before the H1N1 vaccination. Therefore, the fetal death
was unrelated to the vaccination. Previous studies about the
reactogenicity of seasonal inﬂuenza vaccine also reported no
severe adverse events among fetuses and infants [24–26].
Because the present study was conducted during the peak of
the pandemic wave in Japan, the following limitations should
be discussed. The most important limitation might be the
possibility of intercurrent asymptomatic infection. However, we
monitored all subjectsfor inﬂuenza-like illness,and the 1subject
who experienced a conﬁrmed inﬂuenza A virus infection (by the
rapidtest)between the ﬁrstandseconddoseswasexcludedfrom
the analyses. In addition, even when 6 subjects with inﬂuenza-
like illness during the study periods were excluded from the
analyses, the results were almost unchanged. Thus, we believe
that the effect of intercurrent infection was not large enough to
invalidate the present results.
At baseline, the proportion of subjects with a protective level
of titers before vaccination was 7%, which is similar to that
reported in China (4%) [13] but lower than that in Australia
(27%) [14]. The proportion of subjects with protective levels of
prevaccination titers could inevitably differ according to the
location and time of the study, because these levels would be
attributed to asymptomatic infections of the 2009 pandemic
inﬂuenza A (H1N1) before recruitment or to cross-reactive
antibodies induced by previous exposure (through infection or
vaccination) to a virus that is genetically and antigenically
similar to the 2009 pandemic inﬂuenza virus [27]. The stratiﬁed
analyses by prevaccination titer performed in the present study
are adequate to appropriately examine the immunogenicity of
pandemic inﬂuenza A (H1N1) vaccine.
There have been few studies to examine the immunogenicity,
safety, and effectiveness of the seasonal inﬂuenza vaccine among
pregnant women. This lack of studies might contribute to the
low vaccine coverage among pregnant women. However, the
studies have shown that the inﬂuenza vaccination induces suf-
ﬁcient immune responses [28, 29], protects women from febrile
respiratory illness [30–32], and does not cause severe adverse
events for pregnant women or their fetuses [24–26]. Addition-
ally, studies have suggested that the vaccination of pregnant
women could confer the beneﬁcial effect for their infants by
transfer of acquired antibodies through cord blood and could
protect infants ,6 months old from febrile respiratory illnesses,
including inﬂuenza infection [28–32]. We anticipate that addi-
tional scientiﬁc evidence will help to appreciate the necessity of
inﬂuenza vaccination and to increase vaccine coverage among
pregnant women.
In conclusion, the present study indicated the immunoge-
nicity of a single dose of H1N1 vaccination among pregnant
women. No severe adverse events occurred among the partic-
ipants. The potential interference between H1N1 vaccination
and seasonal vaccination needs to be more thoroughly in-
vestigated in a different study setting to prepare for future in-
ﬂuenza pandemics.
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